Clinical retrospective analysis of metformin on TSH levels and nodule volume in patients with type 2 diabetes mellitus combined with thyroid nodules
Abstract
Thyroid nodule (TN) prevalence is rising globally, with particularly high rates among patients with type 2 diabetes mellitus, where insulin resistance and hyperinsulinemia may promote nodule formation via the thyroid-stimulating hormone (TSH)/insulin-like growth factor-1 axis. Metformin, the standard first-line therapy for T2DM, may exert additional effects on thyroid structure beyond glycemic control. This single-center retrospective cohort study enrolled 80 patients with T2DM and benign TNs, assigned to a metformin group (n = 40) or control group (n = 40), and followed for 12 months. Changes in TSH and nodule volume were assessed using multivariable regression, propensity score matching, and sensitivity and subgroup analyses to address confounding. After 12 months, metformin treatment was associated with a significant reduction in TSH (adjusted β = -0.32, 95% confidence interval: -0.57 to -0.06, P = .017) and nodule volume (adjusted β = -8.5, 95% confidence interval: -15.9 to -1.1, P = .024). These effects were consistent in sensitivity analyses, with stronger associations observed in men, patients with body mass index < 28 kg/m², and those with glycated hemoglobin < 8%. In conclusion, metformin significantly lowers TSH levels and reduces nodule size in T2DM patients with benign TNs, supporting its potential clinical utility. Confirmation through large, multicenter, long-term prospective trials is warranted.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 80 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.